PharmiWeb.com - Global Pharma News & Resources

Biotech - Press Releases

Date Title Company
08-Jan-2026 EnteroBiotix announces positive Phase 2 TrIuMPH results supporting EBX-102-02 as a potential first-in-class, oral, full-spectrum microbiome therapy for irritable bowel syndrome EnteroBiotix
08-Jan-2026 NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s NRG Therapeutics
08-Jan-2026 Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted Therapeutics in Solid Tumors and Fibrosis Engitix
07-Jan-2026 Vygon appoints new general manager to lead UK subsidiary Vygon
07-Jan-2026 Bial launches KYNMOBI® (apomorphine hydrochloride) in the United Kingdom Bial
07-Jan-2026 New Annex 1 Sterile Facility Eramol
07-Jan-2026 Vygon appoints new general manager to lead UK subsidiary Andrew Lloyd Associates
06-Jan-2026 HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma HUTCHMED
06-Jan-2026 Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma Johnson & Johnson
06-Jan-2026 MHRA authorises Nucala (mepolizumab) in the UK for the treatment of uncontrolled COPD of an eosinophilic phenotype for patients on triple therapy* GSK
06-Jan-2026 Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent EP4615820 – “Crystalline Forms of Evenamide” is expected to extend asset exclusivity in EU into 2044 Newron
06-Jan-2026 Iksuda to present preliminary analysis of oesophageal cancer data from Phase 1 study of IKS014 at ASCO Gastrointestinal Cancer Symposium Iksuda
06-Jan-2026 Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities Galapagos
06-Jan-2026 LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease LoQus23 Therapeutics
06-Jan-2026 Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation Acesion Pharma
05-Jan-2026 STEMart Enhances Medical Device Safety Testing with New In Vitro Micronucleus Test Service STEMart
05-Jan-2026 CD Bioparticles Launches Comprehensive Animal mRNA Vaccine Solutions to Support Veterinary Research CD Bioparticles
05-Jan-2026 CD Bioparticles Launches Additive Powders to Drive Innovation in 3D Printing and Advanced Manufacturing CD Bioparticles
04-Jan-2026 Creative Diagnostics Launches New Line of Subcellular Fractions for In Vitro Metabolism Studies Creative Diagnostics
04-Jan-2026 Creative Diagnostics Introduces Advanced Hepatitis Virus Animal Models to Accelerate HBV Drug and Vaccine Development Creative Diagnostics